2006 Biosimilars Vaccines 
pharmaphorum
FEBRUARY 23, 2022
Adoption of biosimilars in the US has been notoriously slow, but biosimilars manufacturers and outside observers expect this to change rapidly in the coming years. One way in which the pharmaceutical industry and regulators have reacted is by developing or facilitating the development of biosimilars. The short story so far.
European Pharmaceutical Review
DECEMBER 23, 2024
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. EMA/CHMP/ICH/24235/2006. Internet] Vaccines Europe. Available from: [link] 4. Pharmaceutics. 2021; 13(1): 48. ICH Q8(R2) Pharmaceutical Development – Scientific Guideline. 22 June 2017. EMA/CHMP/ICH/167068/2004. 3 February 2023. J Pharm Sci.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
FEBRUARY 22, 2022
New sections cover: pharmacies’ administration of—and profits from—COVID-19 vaccines; smaller PBMs; PBM purchasing groups and GPOs; 340b split-billing software vendors; and shakeout and consolidation within retail pharmacy. We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars.
PharmaShots
APRIL 13, 2023
by the sales of Humira 2006 Johnson & Johnson recorded global sales of $53.3B in the year 2006, thereby depicting a growth rate of 5.6%. in revenue following the addition of Pfizer’s consumer health business in the year 2006. in revenue following the addition of Pfizer’s consumer health business in the year 2006.
Drug Channels
JUNE 27, 2021
As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing.
Pharmaceutical Technology
JULY 23, 2008
” Looming biosimilar legislation and the disregard for patents in the developing world is also threatening the intellectual property, and therefore profit margins, of companies looking to develop cancer drugs. “You can get vaccines now to prevent cervical cancer. “For certain cancers, yes,” says Ando.
FDA Law Blog: Biosimilars
FEBRUARY 4, 2025
In 2006, David Ridley, Henry Grabowski, and Jeff Moe proposed a voucher in an article in Health Affairs as an incentive to develop therapies for neglected infectious and parasitic diseases that affect hundreds of millions of people in the developing world.
Expert insights. Personalized for you.
98 
Let's personalize your content